Based on a deep understanding of the biology of rare diseases, including molecularly – defined cancers, heritable disorders and pediatric diseases, Forbius (formerly Formation Biologics) identifies therapeutic targets that are central to the disease process and applies advanced protein engineering methods to design biotherapeutics positioned to become the new standard of care.

Forbius was formed in 2011 as a spin-out company from YM BioSciences, Inc. and is based on technologies co-developed with the National Research Council and other research centers of excellence.